Figure 8.
Inflammatory status in MECP2- and CDKL5-mutated Rett patients before and after ω-3 PUFAs supplementation. Data are expressed as means ± standard deviations. Asterisks denote significant post hoc pairwise tests (P < 0.05). The dashed line denotes upper range limit as obtained from clinical laboratory.